Industry4h ago
Takeda and Insilico Ink $600M AI Deal
A $600 million agreement links Takeda with Insilico Medicine to accelerate drug discovery. The Japanese pharma giant will leverage Insilico's AI platform to identify novel therapeutic candidates. This partnership focuses on shortening the traditional R&D timeline. Practitioners should note the increasing scale of capital flowing into AI-driven biotechnology for early-stage lead discovery.